Tagged as: Jeuveau

Medytox Files ITC Complaint Against Hugel to Block Import of Botox Follow-On

On March 30, 2022, Medytox filed a complaint with the ITC requesting that the ITC block imports of Hugel’s follow-on biologic Letybo® (LetibotulinumtoxinA) product.  The complaint alleges that Hugel expects to obtain approval and launch its product in the U.S. in 2022.  The complaint alleges that “Hugel misappropriated Medytox’s trade…

Read More

ALJ Recommends Exclusion in Botox Trade Secret Case

We previously reported on an International Trade Commission hearing in a trade secret dispute brought by Allergan and Medytox against Daewoong and Evolus.  In the underlying investigation, Allergan and Medytox seek to block importation of Jeuveau® (prabotulinumtoxinA-xvfs), Evolus’s follow-on biologic to Allergan’s Botox® (onabotulinumtoxinA injection).  A one-page public notice provides…

Read More